Effects of antibiotics on infant microbiota
Antibiotic-induced Disruption of the Maternal and Infant Microbiota and Adverse Health Outcomes - The ABERRANT Study
This study is trying to see how antibiotics given during birth affect the gut and mouth bacteria of infants and if these changes could lead to health issues later on.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 1 Day to 2 Years |
| Sex | All |
| Sponsor | University of Fribourg Academic / other |
| Locations | 1 site (Fribourg) |
| Trial ID | NCT04091282 on ClinicalTrials.gov |
What this trial studies
This observational study investigates how intrapartum antibiotics affect the composition of breast milk and the oral and intestinal microbiota of infants. It aims to assess the impact of early-life antibiotic exposure on the infant's microbiota during the first year and whether these changes lead to long-term effects or health issues. The study will also explore the relationship between maternal and infant microbiota. By analyzing these factors, the researchers hope to gain insights into the consequences of antibiotic use in early life.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy term infants born to mothers who did not receive antibiotics during the third trimester of pregnancy.
Not a fit: Patients who may not benefit from this study include those with maternal infections such as HIV or hepatitis, or infants with low birth weight or congenital abnormalities.
Why it matters
Potential benefit: If successful, this study could provide valuable information on how to optimize antibiotic use in infants to minimize negative impacts on their microbiota and overall health.
How similar studies have performed: Other studies have indicated significant effects of antibiotics on microbiota, suggesting that this approach is relevant and builds on existing knowledge.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * healthy infants * term infants (\> 37 weeks of gestation) Exclusion Criteria: * maternal HIV infection * maternal hepatitis B or C infection * antibiotics in the third trimester of pregnancy * intake of probiotics during pregnancy * infants with the low birth weight \<2500 g * infants with congenital abnormality
Where this trial is running
Fribourg
- Hopital cantonal Fribourg — Fribourg, Switzerland (Recruiting)
Study contacts
- Principal investigator: Petra Zimmermann, MD, PhD — Hopital Cantonal de Fribourg, Switzerland
- Study coordinator: Petra Zimmermann, MD, PhD
- Email: petra.zimmermann@h-fr.ch
- Phone: +413063542
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.